Canaccord Genuity Initiates Coverage On Relay Therapeutics with Buy Rating, Announces Price Target of $29
Benzinga Newsdesk 4 months ago
NewsInitiationAnalyst RatingsPrice Target
Canaccord Genuity analyst John Newman initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Buy rating and announces Price Target of $29.
Canaccord Genuity analyst John Newman initiates coverage on Relay Therapeutics (NASDAQ:RLAY) with a Buy rating and announces Price Target of $29.